Charity registration number 1046278 (England and Wales)
Company registration number 03050367
FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
LEGAL AND ADMINISTRATIVE INFORMATION
Trustees
MSA T Mogg
Ms F M S Goodey CBE DL
Ms LA D0v￿all
Mr M Vara
MrRCRea
Ms K London
Mrs J Crosby
Ms C Nuttall
Mr J Hickman PhD
A Dykes
{Appointed 1 February 2025)
{Appointed 1 July 2025)
Secretary
MSA T Mogg
Honorary President
Lisa Larkin MBE
Charity number
1046278
Company number
03050367
Registered office
86 Deansgate
Manchester
Independent examiner
David Kay FCA
Barfow Andrews LLP
Cadyle House
78 Chodey New Road
Bolton
Bankers
Royal Bank of Scotland
Drummond House
1 Redheughs Avenue
Edinburgh
Solicitors
Slater Heelis Limited
86 Deansgate
Manchester

FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
CONTENTS
Page
Trustees, report
Statement of trustees. responsibilities
Independent examinerfs report
Statement of financial activities
Balance sheet
Notes to the financial statements
9-13

FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
TRUSTEES. REPORT (INCLUDING DIRECTOR'S REPORT)
FOR THE YEAR ENDED 31 MARCH 2025
The trustees present their annual report and financial statements for the year ended 31 March 2025.
The financial statemenls have been prepared in accordance with the accounling policies sel out in note 1 to the
financial statements and comply with the charity's goveming document, the Companies Act 2006 and "Accounting
and Reporting by Charities= Statement of Recommended Practice applicable to charities preparing their accounts in
accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 1021 (effective
1 January 2019)".
Objectives and activities
'Friends of Rosie. Children's Cancer Research Fund., was established with one key objective, to fund early-stage
research with the potential of finding kinder. more effective treatment and possible cures for children with cancer.
The founders were Lisa and Patrick Larkin, parents of a little girl called Rosie who lost her life at the age of 5. There
is still no cure for the cancer which killed Rosie. Progress has been made in many areas but there are still too many
treatments designed for adults which have devastating side effects on children and still conditions for which there is
no cure. Getting that message across to the wider public requires effective communication and communications
have undergone radical change since Friends of Rosie was created. This year the Charity undertook a
professionally-led rebranding exercise and. with the full support of Rosie's parents, decided to amend its name.
'Friends of Rosie, will henceforth be known simply as'children's Cancer Research Fund, (C.C.R.F.).
Cancer is the biggest killer of children under 14. Yet it continues to re￿1ve a small fraction of the support which
goes into combatting adult cancer whether from public funds, charity or the pharmaceutical companies. The Charily
was created at the request of scientists and clinicians who find attracting funds for the earliest stages of research
extremely challenging. It is now an accredited member of the Association of Medical Research Charities (AMRC).
At the core of the Charity from the outset is a highly distinguished Intemational Scientific Advisory Board {SABI.
The current chair, Dr Mark Gaze, has been a Consultant Clinical Oncologist at Great Ormond Street Hospital
(GOSH) since 1993. He is also a consultant at University College Hospital, Chairman of the Children's Cancer and
Leukaemia Group, lead for radiotherapy in clinical trials run by the European Paediatric Soft Tissue Sarcoma Group
(EpSSGI and the International Society of Paediatric Oncology Europe Neuroblasloma Group (SIOPENI. Dr Gaze
will retire as Chair of the SAB in September 2025. The CCRF would like to thank him and acknowledge his
invaluable work together with the work and support of three other SAB colleagues whose terms of office also end in
September. Under Dr Gaze's leadership several important new studies have been completed and a very successful
International Symposium held to discuss how to make molecular radiotherapy work better for children with
neuroblastoma. A detailed report from the symposium has been published in the high-impact publication, American
Journal of Nuclear Medicine.
The SAB is currently designing the next in the Charity's series of two-day Intemational Symposia held bi-annually in
Manchester. The theme for 2026 will be the treatment of childhood leukaemia.
Trustees have authorised a new call for Grant proposals, applications for which are due by the 31st of October 2025.
Public benefit
The trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the
charity should undertake and firmly believe that the charity continues to meet the requirement to provide public
benefit.

FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
TRUSTEES. REPORT (INCLUDING DIRECTOR'S REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
Achievements and perforniance
Signifi'cant activities and achievements against objectives
Proton Beam Therapy Project
At the start of January, Dr Amy Chadwick and Dr Emma Biglin began the se(x)nd year of a research project funded
by the CCRF to explore the potential of proton beam therapy in treating paediatric cancers. Over the first year of this
study, they made significant strides in their research, focusing on how cells respond to this advanced form of
radiotherapy under low oxygen conditions and in combination with different drugs. This project is being carried out
at The Christie Hospital in Manchester. Proton beam therapy (PBT) uses high energy proton beams in pla￿ of
conventional X-rays. The unique physical properties of protons means that protons stop at a precise depth in tissue,
with no radiation dose delivered beyond. Lead researcher, Dr Amy Chadwick says the project is very ambitious.
"Our goal is to increase the effectiveness of proton beam therapy. with potential to decrease the dose of radiation to
reduce the side effects for children with cancer. In their first year, the team carried out high-throughpul drug
screenir7g on 355 compounds in combination with proton beam therapy under hypoxic conditions. This leading-edge
work has yielded promising results in year one. and we believe they are the only team in the world with this
capability, making this research particularly significant.
During their second year of research. Amy and Emma aim to validate the drug combinations they found to be
effective. They will expand their research to different models and further understand how these combinations work.
Dr Chadwick says.. "We're already having discussions with other collaborators to look at the potential to translate
our findings into real-world treatments that could benefit children with Can￿r. By the end of our second year. we aim
lo publish our work and secure larger grants to continue this pioneering research."
Blood-tests for neuroblastoma clinical trials to guide next-generation cancer treatments
In 2021, we were delighted to collaborate with Neuroblastoma UK on a research grant of £469,093, awarded to an
international team of leading clinician-scientists to explore how blood tests (biomarker testing) could be used in
clinical trials to improve outcomes for children with neuroblastoma.
Professor Louis Chesler's research grant was co-funded by Neuroblastoma UK (£454,093) and Children's Cancer
Research Fund (£15,000) as part of Neuroblastoma UK'S 2021 Grant Round.
Thanks to the grant provided by Neuroblastoma UK and Children's Can￿r Research Fund, scientists have been
able to evaluate the accuracy and reliability of the blood-tests, making them ready for use in clinical trials when they
are appropriately integrated into a clinical workflow.
The legacy of this research will also contribute to further collaboration across the UK and Europe. Helping to bring
logether field leaders and creating a more standardised way of testing cancerous DNA across Europe and the UK.
This will support future collaboration. accelerating progress for the next generation of clinical trials.
Blood-tests are now being implemented in clinical trials including the SIOPEN pragmatic clinical trial to 'Monitor
Neuroblastoma Relapse with Liquid Biopsy Sensitive Analysis, IMONALISA). This promising clinical trial hopes to
improve eady detection of relapse, overall survival rates, outcomes for patients and changes in care slralegy.
Partnerships
In the past year the Charity has part funded individual research projects as well as the International Symposium by
inviting collaboration from other smaller charities or being willing to collaborale with another funder. The Charity is
encouraging smaller organisations, who do not have access to the same level of scientific and clinical advice built
up by CCRF (aka Friends of Rosie} to join with us to put some of their money into research projects which they can
be confident have been fully vetted and appraised by experts. CCRF makes no charge for this and freely shares
any resulting publicity with co-funders.

FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
TRUSTEES. REPORT (INCLUDING DIRECTOR'S REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
Challenge events
Led by Trustee Katrina London and strongly supported by several other Trustees, CCRF (aka) Friends of Rosie has
begun fielding leams in Challenge Events across the UK and in Europe. Supporters can run. cycle or even bounce
their way to raising funds to support vital research into childhood cancers. Our latest team is the crew of a super
Yacht in the Mediterraneanl
Ward 86 Christmas Party
A Christmas parly for the children and families of the Manchester Children's Hospital cancer wards is nol strictly
within the Charity's remit. But when it transpired that the annual Christmas paty for these very vulnerable children
had lapsed when the original organisers retired, Friends of Rosie (CCRFI Trustees agreed unanimously that the
charity should try lo revive it. Three other small charities quickly answered the call and together a Christmas Party
was held in December 2023 hosted by BrUn￿oOd SciTech opposite the Manchester Children's Hospital. Sadly in
2024 too many of our key organisers were unable to help but we are delighted to announce that plans for a Ward 84
party this Christmas, 2025, are well advanced and generously sponsored. Our thanks in particular to Bruntwood
SciTech who are once again providing the facilities.
CCRF is also delighted to announ￿ that Bruntwood SciTech has adopted the charity as an official sponsor and
corporate supporter and will be working together with us on an exciting range of new fundraising opportunities in the
Goming year.
Children's Cancer Research Fund. (aka Friends of Rosie)
The Charity would like to thank all its hard-working Trustees. volunteers and many supporters and sponsors,
especially the PJ Livesey Group whose owners and staff have been fvnd raising for the Charity from the start and
Gontinue to be active and enthusiastic supporters.
The Charity continues to be volunteer-led, ensuring that ninety five percent of fvnds raised go directly into research
or related activity. enabling children with cancerto thrive and survive.
Financial review
In the current financial year total income decreased from £79,712 to £70,316. Donations and legacies remain the
principal source of our funding. Expenditure decreased from £119.236 to £50.834. with the loss of the granls
awarded in the previous year. Funds, all of which are unrestricted, increased by £19,482 and at the balance sheet
date stood at £100,480, which the trustees believe is sufficient to meet the charity's needs and statutory obligations
for the foreseeable future.
Reserves policy
It is the policy of the Gharity that unrestricted funds which have not been designated for a speGifiG use should be
maintained at a level at least equivalent to between three and six months. running costs. The trustees consider that
reserves at this level will ensure that. in the event of a significant drop in funding. they will be able to continue the
Gharity's Gurrent aGlivities while consideration is given to ways in which additional funds may be raised. There has
been an increase in reseNes this year and the target level of free reserves has been maintained throughout the
year, the charity's level of free reserves being £100.480 {2024 - £80.998) at the financial year end.
Major risks
The truslees have assessed the major risks to which the charity is exposed, and are satisfied that systems are in
place to mitigate exposure to the major risks.
Plans for future periods
In addition to some specific plans outlined in the various sections of the foregoing review of achievements and
performan￿, the charity will continue to raise funds for the research and treatment of cancer in children.

FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
TRUSTEES. REPORT (INCLUDING DIRECTOR'S REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
Structure, governance and management
The charity is a registered charity. number 1046278 and is govemed by its Memorandum and Articles of Association
dated 27 April 1995. The company (registered number 03050367) has no share capital and is limited by guarantee.
None of the trustees has any beneficial interest in the company. Anyone over the age of 18 can become a member
of the company. Members agree to contribute £1 in the event of winding up.
The trustees, who are also the directors for the purpose of company law. and who seNed during the year and up to
Ihe date of signature of the financial statements were=
MSA Tmogg
Ms F M S Goodey CBE DL
Ms L A Dowdall
Mr M Vara
MrRCRea
Ms K London
Mrs J Crosby
Ms C Nuttall
Mr J Hickman PhD
A Dykes
(Appointed 1 February 2025)
(Appointed 1 July 2025)
Recruitment and appointment of tmstees
Trustees are appointed based on their expertise from recommendations of the existing trustees.
CCRF is delighted to welcome two new Trustees:
Antonia Dykes, has joined as a new parent Trustee. Antonia has a degree in fine art and is passionate about art
education for young people. having worked in schools in the UK and on the island of St. Helena. She is mum to 3
daughters. one of whom was diagnosed with rhabdomyosarcoma aged 2 in January 2017. After more than a year of
various treatments she relapsed in September 2018 and finally finished all treatment in November 2019. Antonia's
family travelled to Gemiany twice for her daughter to have proton beam therapy which wasn't available in the UK at
the time. She brings with her a unique perspective and invaluable insight as a parent with lived experience of
childhood
cancer.
Professor John Hickman DSC. fomier Professor of Molecular Phamiacology at the University of Manchester,. lead
pharmacologist for the discovery of the drug Temozolomide, used to treat brain cancers,. director of cancer drug
discovery at Servier and coordinator of a European Union Innovative Medicines Initiative {IMII consortium. Prof.
Hickman is also a past Chamian of the CCRF Scientific Advisory Board.
The trustees. report was approved by the Board of Trustees.
MrRCRea
Trustee
28 October 2025

FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
STATEMENT OF TRUSTEES. RESPONSIBILITIES
FOR THE YEAR ENDED 31 MARCH 2025
The trustees, who are also the directors of FRIENDS OF ROSIE for the purpose of company law. are responsible
for preparing the Trustees, Report and the financial statements in accordance with applicable law and United
Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).
Company law requires the trustees lo prepare financial statements for each financial year which give a true and fair
view of the state of affairs of the charity and of the incoming resources and application of reSoUr￿s. including the
income and expenditure, of the charitsble company for that year.
In preparing these financial statements. the trustees are required to=
select suitable accounting policies and then apply them consistently:
observe the methods and principles in the Charities SORP-
make judgements and estimates that are reasonable and prudent.,
state whether applicable UK Accounting Standards have been followed. subject to any material departures
disclosed and explained in the financial statements., and
prepare the financial statements on the going concem basis unless it is inappropriate to presume that the charity
will continue in operation.
The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at
any time the financial position of the charity and enable them to ensure that the financial statements Gomply with the
Companies Acl 2006. They are also responsible for safeguarding the assets of the charity and hence for taking
reasonable steps for the prevention and detection of fraud and other irregularities.

FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF FRIENDS OF ROSIE
I report lo the trustees on my examination of the financial statements of FRIENDS OF ROSIE (the charity) for
the year ended 31 March 2025.
Responsibilities and basis of report
As the trustees of the charity (and also its directors for the purposes of company law}, you are responsible for
the preparation of the financial statements in accordance with the requirements of the Companies Act 2006.
Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16
of the Companies Act 2006 and are eligible for independenl examination, I report in respect of my examination
of the charity's financial statements carried out under section 145 of the Charities Act 2011. In carying out my
examination I have followed the Directions given by the Charity Commission under section 145(5}(b} of the
Charities Act 2011.
Independent examinerfs ststement
I have completed my examination. I confimi that no matters have come to my atlention in connection with the
examination giving me cause to believe that in any material respect:
accounting records were not kept in respect of the charily as required by section 386 of the Companies
Act 2006.
the financial statements do not accord with those records; or
the financial statements do not comply with the accounting requirements of section 396 of the Companies
Act 2006 other than any requirement that the financial statements give a true and fair view, which is not a
matter considered as part of an independent examination- or
the financial statements have not been prepared in accordan￿ with the methods and principles of the
Statement of Recommended Practice for accounting and reporting by charities applicable to charities
preparing their financial statements in accordan￿ with the Financial Reporting Standard applicable in the
UK and Republic of Ireland (FRS 102).
I have no Goncems and have come across no other matters in connection with the examinalion to which
attention should be drawn in this report in order to enable a proper understanding of the financial statements to
be reached.
David Kay FCA
Barlow Andrews LLP
Chartered Accountants
Carlyle House
78 Chorley New Road
Bolton
Dated: 28 October 2025

FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 MARCH 2025
Unrestricled Unrestricted
funds
funds
2025
2024
Notes
Income from:
Donations and legacies
Investments
69,421
895
78,824
888
Total income
70,316
79,712
enditure on:
Charitable activities
50,834
119.236
Net incomel(expenditure) for the yearl
Net movement in funds
19,482
{39,5241
Fund balances at 1 April 2024
80,998
120,522
Fund balances at 31 March 2025
100,480
80,998
The statement of financial activities includes all gains and losses recognised in the year.
The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure
derive from continuing activities.
The statement of financial activities also complies with the requirements for an income and expenditure account
under the Companies Act 2006.

FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
BALANCE SHEET
ASAT31 MARCH 2025
2025
2024
Notes
Current assets
Cash at bank and in hand
176,371
171,901
Creditors: amounts falling due within
one year
10
(75,891)
(90,9031
Net current assets
100,480
80,998
The funds of the charity
Unrestricted funds
11
100,480
80,998
100,480
80,998
The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act
2006. for the year ended 31 March 2025.
The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with
respect to accounting records and the preparation of financial statements.
The members have not required the company to obtain an audit of its financial statements for the year in question in
accordance with section 476.
These financial slatements have been prepared in accordance with the provisions applicable to companies subject
lo the small companies regime.
The financial statements were approved by the trustees on 28 October 2025
MrRCRea
Trustee
Company registration number 03050367 (England and Wales)

FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
Accounting policies
Charity information
FRIENDS OF ROSIE is a private company limited by guarantee incorporated in England and Wales. The
registered office is 86 Deansgate, Manchester.
1.1 Accounting convention
The financial statements have been prepared in accordance with the charity's governing document, the
Companies Act 2006. FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of
Ireland" ("FRS 102.) and the Charities SORP "Accounting and Reporting by Charities: Statement of
Recommended Practi￿ applicable to charities preparing their accounts in accordan￿ with Ihe Financial
Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The
charity is a Public Benefit Entity as defined by FRS 102.
The charity has taken advantage of the provisions in the SORP for charities not to prepare a Statement of
Cash Flows.
The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary
amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting
policies adopted are set out below.
1.2 Going concern
At the lime of approving the financial statements. the trustees have a reasonable expectation that the charity
has adequate resources to continue in operational existen￿ for the foreseeable future. Thus the trustees
continue to adopt the going concem basis of accounting in preparing the financial statements.
1.3 Charitable funds
Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable
objectives.
Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The
purposes and uses of the restricted funds are set out in the notes to the financial statements.
1.4 Income
Income is recognised when the charity is legally entitled to it after any perfomiance conditions have been met,
the amounts can be measured reliably, and it is probable that income will be received.
Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution,
the amount is known. and receipt is expected. If the amount is not known, the legacy is treated as a
contingent asset.

FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
NOTES TO THE FINANCIAL STATEMENTS {CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
Accounting policies
(Continued)
1.5 Expenditure
Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a
third party. it is probable that a transfer of economic benefits will be required in setuement. and the amount of
the obligation can be measured reliably.
Expenditure is classified by activity. The costs of each activity are made up of the total of direcl cosls and
shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single
activity are allocated directly to that activity- Shared costs which contribute to more than one aGtivity and
support costs which are not attributable to a single activty are apportioned between those activities on a basis
consistent with the use of resources.
Support costs are those functions that assist the work of the charity but do not directly undertake charitable
activities. Support costs include Offi￿ costs. finance. personnel, payroll and govemance costs which support
the charity's activities.
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at
transaction price including transaction costs and are subsequently carried at amortised Gost using the effective
interest method unless the arrangement constitutes a financing transaction, where the transaction is
measured at the present value of the future receipts discounted at a market rate of interest. Financial assets
classified as receivable within one year are not amortised.
Basic financial liabilities
Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless
the arrangement constitules a financing transaction. where the debt instrument is measured at the present
value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable
within one year are not amortised.
Donations and legacies
Unrestricted Unrestricted
funds
funds
2025
2024
Donations and gifts
69,421
78.824
10-

FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
NOTES TO THE FINANCIAL STATEMENTS {CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
Expenditure on charitable activities
2025
2024
Marketing and communications
Conference costs
Sundry expenses
Bank charges
Insurance
22,125
24,671
1,529
25,926
2,273
77
616
655
49,044
28.892
Grant funding of activities {see note 4)
88,857
Share of support and governance costs (see note 5)
GovernanGe
1,790
1,487
50,834
119,236
Analysis by fund
Unrestricted funds
50,834
119,236
Grants payable
2025
2024
The University of Manchester
Dr Chadwick Research
18,857
70,000
88,857
Support costs
Governance
costs
2025
2024 Basis of allocation
Independent examination fees
1,790
1,790
1,487 Governance
1.790
1.790
1.487
11

FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
NOTES TO THE FINANCIAL STATEMENTS {CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
Net movement in funds
2025
2024
The net movement in funds is stated after chargingl{crediting):
Fees payable for the independent examination of the charity's financial
statements
1,790
1,487
Trustees
None of the trustees and directors (or any persons connected with them) received any remuneration or
benefits from the charity during the year.
No trustee expenses were incurred during the current or previous year.
Employees
There were no employees during the cu￿ent or previous year.
Taxation
The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.
10 Creditors: amounts falling due within one year
2025
2024
Grants payable
Accruals and deferred income
70,000
5,891
87,366
3,537
75,891
90,903
11 Unrestricted funds
The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are
not subject to specific conditions by donors and grantors as to how they may be used. These ir)clude
designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.
At 1 April
2024
Incoming
resources
Resources At 31 March
expended
2025
General funds
80.998
70,316
(50,8341
100,480
Previous year:
At 1 April
2023
Incoming
resources
Resources At 31 March
expended
2024
General funds
120.522
79.712
(119,2361
80,998
12-

FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
NOTES TO THE FINANCIAL STATEMENTS {CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
12 Related party transactions
There were no disclosable related party transactions during the year (2024 - none).
13-